ClinicalTrials.govpublic full text
Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
recurrent diffuse large b-cell lymphoma, refractory diffuse large b-cell lymphoma, interventional, phase1
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 804017
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.